Cancer News and Research

Latest Cancer News and Research

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

LA BioMed to receive $9.7M federal grant for construction of new Chronic Disease Clinical Research Center

With a goal of creating jobs and enhancing chronic disease studies, the federal government is awarding a $9.7 million grant of stimulus funds to the Los Angeles Biomedical Research Institute (LA BioMed) for the construction of a new Chronic Disease Clinical Research Center on its campus, David I. Meyer, PhD, the institute's president and CEO, announced today.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

ZIOPHARM Oncology, Inc., announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

9 Apr 2010

WTC FDNY Rescue Workers have not recovered normal lung function, yet

A study of nearly 13,000 rescue workers from the Fire Department of the City of New York (FDNY) shows that the significant proportion who suffered acute lung damage after exposure to World Trade Center (WTC) dust have not recovered normal lung function in the years since the September 11, 2001 terrorist attacks.

8 Apr 2010

Merge Healthcare to exhibit expanded suite of women's imaging solutions at NCBC 2010

Merge Healthcare, a health IT solutions leader, today announced it will be showcasing it's expanded suite of innovative solutions and support of comprehensive continuing education programs for the advancement of women's imaging at the National Conference on Breast Cancer (NCBC) 2010. Additionally, Merge plans to introduce and collaborate with attendees on its Women's Healthcare Initiative, which builds partnerships with clinicians to provide broader access to training in the analysis and interpretation of these important studies.

8 Apr 2010

Political controversies surrounding healthcare reform law may continue

A comprehensive review of national opinion polls taken before and after Congressional voting and when President Obama signed into law a major healthcare reform bill last month has found that the law's signing did not lead the country to come together in support of this landmark legislation. Partisan differences are stark, according to researchers at Harvard School of Public Health (HSPH) who analyzed 33 independent opinion polls in an effort to gauge public support for healthcare change.

8 Apr 2010

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Oncolytics Biotech Inc. announced today that a paper entitled "Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice," co-senior authored by Dr. Richard Vile of the Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA, and Dr. Kevin Harrington of the Institute of Cancer Research, London, UK, was published in the online version of the Journal of Clinical Investigation on April 1, 2010.

8 Apr 2010

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Labopharm Inc. today announced its wholly owned subsidiary, Labopharm Europe Limited, has completed a licensing and distribution agreement for once-daily tramadol with Nippon Shinyaku Co., Ltd. of Japan.

8 Apr 2010

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

Despite a concern that obese or overweight patients may receive lower quality of health care, an analysis of eight common outpatient quality measures from a sample of nearly 70,000 patients finds no evidence that obese or overweight patients receive inferior care when compared with normal-weight patients, and in fact may receive a higher rate of recommended care on several measures, according to a study in the April 7 issue of JAMA.

8 Apr 2010

UBC doctoral candidate discovers a mechanism for silencing retroviruses

A University of British Columbia doctoral candidate has discovered a previously unknown mechanism for silencing retroviruses, segments of genetic material that can lead to fatal mutations in a cell's DNA.

8 Apr 2010

Allergy flare-ups due to indoor allergens

Spring is here and allergy flare-ups are often attributed to the allergens outside your front door. However, did you know that the same allergens are found on surfaces inside 75 million homes across America? According to the Centers for Disease Control and Prevention (CDC), some of the most common indoor allergens include dust mites, mold and household pets.

8 Apr 2010

Potential toxicity of zinc nanoparticles in sunscreen products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death. Their study is in ACS' Chemical Research in Toxicology, a monthly journal.

8 Apr 2010

Bayard Advertising Agency selected as Recruitment Advertising Agency of Record by CTCA

Bayard Advertising Agency, Inc., an integrated branding and communications agency serving B2B and B2C clients in a broad array of industries, announces its selection as Recruitment Advertising Agency of Record by Cancer Treatment Centers of America.

8 Apr 2010

OncoGenex Pharmaceuticals recognized with BIOTECanada's Gold Leaf Award

OncoGenex Pharmaceuticals, Inc. announced today that the Company will be presented with BIOTECanada's Gold Leaf Award as biotech company of the year. The award recognizes a biotech company that has distinguished itself from its peers with strong overall performance as a company, demonstrated leadership and shown significant achievement.

8 Apr 2010

Organic Science signs management agreement to operate Healing Arts Cooperative Medical Marijuana dispensary

International Merchant Advisors, Inc. www.imaiinc.com announced today that the company's subsidiary, Organic Science, Inc. has signed a management agreement to operate the Healing Arts Cooperative Medical Marijuana dispensary located in San Diego, California and to operate the cooperative as the manager of the facility on behalf of its non profit owners.

8 Apr 2010

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

A team of tumor immunologists in France and Switzerland has established an improved, reliable immune monitoring tool that allows for more accurate measurement of the number, subtype, and activity of cancer antigen-specific CD4+ T cells in cancer patients treated with therapeutic cancer vaccines. The new technology may significantly aid tumor immunologists around the world who are working to improve the effectiveness of this emerging and highly promising class of immune system-based cancer therapies.

8 Apr 2010

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

BeaconEquity.com announces an investment report featuring biopharmaceutical company Genta Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

8 Apr 2010

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company has completed enrollment of all subjects for its therapeutic cervical cancer vaccine (VGX-3100) phase I trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18, and is delivered via in vivo electroporation.

8 Apr 2010

Meltdown Station provides educational material to help children learn healthy lifestyle skills

With the childhood obesity epidemic finally at the front line, first lady Mrs. Obama has taken the initiative to do something about it, but what is she doing? The first lady Mrs. Obama started the Let's Move! Initiative and stated in a press conference "that the goal of the program is to reverse the trend toward childhood obesity in one generation."

8 Apr 2010

Cancer News and Research

Latest Cancer News and Research

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

LA BioMed to receive $9.7M federal grant for construction of new Chronic Disease Clinical Research Center

Æterna Zentaris commences perifosine Phase 3 registration trial

ZIOPHARM Oncology commences Phase I/II study of Zybulin for metastatic breast cancer

WTC FDNY Rescue Workers have not recovered normal lung function, yet

Merge Healthcare to exhibit expanded suite of women's imaging solutions at NCBC 2010

Political controversies surrounding healthcare reform law may continue

Combining antiangiogenic cancer therapy with oncolytic virotherapy leads to regression of tumors

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Obese patients may receive higher rate of recommended care than normal-weight patients, but not lower

UBC doctoral candidate discovers a mechanism for silencing retroviruses

Allergy flare-ups due to indoor allergens

Potential toxicity of zinc nanoparticles in sunscreen products

Bayard Advertising Agency selected as Recruitment Advertising Agency of Record by CTCA

OncoGenex Pharmaceuticals recognized with BIOTECanada's Gold Leaf Award

Organic Science signs management agreement to operate Healing Arts Cooperative Medical Marijuana dispensary

Reliable immune monitoring tool for assessment of cancer vaccine-induced CD4+ T-cell response

GETA receives "Fast Track" designation from FDA for Tesetaxel: BeaconEquity.com

Enrollment completes for Inovio Biomedical's dose escalation phase I trial of cervical cancer vaccine

Meltdown Station provides educational material to help children learn healthy lifestyle skills

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in